Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial ...

The antibody-drug conjugate (ADC) field is advancing at an unprecedented pace, with groundbreaking innovations and soaring investment. A 33% rise in new drugs, a surge in clinical trials, and ...

ONA-255 is a first-in-class molecule aimed at a new ADC target found in numerous common solid tumours. The collaboration is centred around Reveal Genomics’ chief scientific offi ...

An Antibody-Drug Conjugate (ADC) comprises a drug linked to an anitbody. The anitbody binds selectively to cancer cells to deliver the drug into the cell.

It’s not surprising that Analog to Digital Converters (ADC’s) now employ several techniques to accomplish higher speeds and resolutions than their simpler counterparts. Enter the Delta-Sigma ...

The phase 1b trial is investigating the ADC and Keytruda – with or without chemo – in both previously-untreated and pretreated patients with advanced NSCLC who don’t have genetic mutations ...

"Today marks a transformative moment as we reintroduce ourselves as Whitehawk Therapeutics – a focused oncology company combining science ... portfolio of promising ADC assets," said David ...

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These ...